

**University of British Columbia**  
**Curriculum Vitae for Faculty Members**

**Date:** August 21, 2025

**Verification Initial:** KJ

<b>1.</b>	<b>SURNAME:</b>	Johnson	<b>FIRST NAME:</b>	Kate
			<b>MIDDLE NAME(S):</b>	Marie

<b>2.</b>	<b>DEPARTMENT/SCHOOL:</b>	
<b>3.</b>	<b>FACULTY:</b>	Faculty of Pharmaceutical Sciences
	<b>JOINT APPOINTMENTS:</b>	Division of Respiratory Medicine, Faculty of Medicine

<b>4.</b>	<b>PRESENT RANK:</b>	Assistant Professor (Grant tenure-track)	<b>SINCE:</b>	January 1 <sup>st</sup> , 2022
-----------	----------------------	--	---------------	--------------------------------

**5. POST-SECONDARY EDUCATION**

University or Institution	Degree	Subject Area	Dates
University of Washington	Postdoctoral Fellow	Health Economics and Outcomes Research	01/2020 – 12/2021
University of British Columbia	PhD <sup>1</sup>	Pharmaceutical Sciences (Health Economics and Outcomes Research)	09/2016 – 03/2020
University of British Columbia	MSc	Biology	09/2013 – 08/2015
University of Alberta	BSc	Conservation Biology	09/2008 – 04/2013

<sup>1</sup>PhD Dissertation

Title: Evaluating Strategies for Early Detection of Chronic Obstructive Pulmonary Disease

Supervisor: Dr. Mohsen Sadatsafavi

**6. EMPLOYMENT RECORD**

**(a) Prior**

University, Company or Organization	Rank or Title	Dates
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington	Postdoctoral Fellow	01/2020 – 12/2021

**(b) Present**

University, Company or Organization	Rank or Title	Dates
Faculty of Pharmaceutical Sciences, Division of Respiratory Medicine, Department of Medicine, UBC (Joint Appointment)	Assistant Professor	Jan 2022 - Present
Legacy for Airway Health	Faculty	Jan 2022 - Present
Collaboration for Outcomes Research & Evaluation (CORE)	Faculty	Jan 2022 - Present

**7. LEAVES OF ABSENCE**

University, Company Or Organization at which Leave was taken	Type of Leave (duration)	Dates
University of British Columbia	Parental (9 mo)	11/2023 – 09/2024
University of Washington	Parental (4 mo)	02/2021 – 06/2021

## 8. TEACHING

### (a) Areas of special interest and accomplishments

<b>Highlight 1</b>
<b>Course Co-lead and Instructor (ongoing, BPSc)</b>
<b>Course:</b> Clinical Epidemiology & Pharmaceutical Outcomes II PHAR 305 (3 credit required course)
<b>Description:</b> This is a required course for third year students in the Bachelor of Pharmaceutical Sciences (BPSc) Program, which was offered for the first time in January 2023. The goal of the course is to familiarize students with population-level observational study designs, their analysis, and develop their critical appraisal skills in evidence evaluation, with a special emphasis on evidence-based pharmacy practice.
<b>Role:</b> As the course co-coordinator I am responsible for all curriculum development, lectures, class activities, course organization and evaluation. I place a special emphasis on hands-on activities that address current research questions and develop practical skills in data analysis and research implementation. Because the BPSc program is new, all course materials were developed from scratch for the first year of instruction in January 2023.

<b>Highlight 2</b>
<b>FLEX Activity Supervisor and Advisor (ongoing, MEDD)</b>
<b>Course:</b> Flexible Enhanced Learning (FLEX), MEDD 419
<b>Description:</b> FLEX blocks provide 1 <sup>st</sup> , 2 <sup>nd</sup> , and 4 <sup>th</sup> year medical students with an opportunity to pursue scholarly activities through individualized learning.
<b>Role:</b> I serve two roles within the FLEX program. I act as an Advisor for small group sessions in which students engage in hands-on activities to develop their research skills. I facilitate discussions and individualized learning to prepare them for dedicated research blocks. As an Activity Supervisor, I supervise students on various topics within my research program. In developing student research projects, I emphasize feasibility and applicability to the student's background and interests. I provide mentorship through regular meetings and guidance as they develop their research skills in the context of the project.

### (b) Courses taught at UBC:

Year	Course Number	Description	Scheduled Hours	Class Size	Hours Taught				Role
					Lectures	Tutorials	Labs	Other	
2025 W	PHAR 305	Clinical Epidemiology & Pharmaceutical Outcomes II	24	50	18				Course Co-coordinator
2024 F	PHAR 422	Pharmacoeconomics	24	9	16.5				Course Co-coordinator
2024 F	MEDD 419	FLEX Advisor	13.5	8		15			Instructor
2023 F	MEDD 419	FLEX Advisor	13.5	8		13.5			Instructor
2023 W	MEDD 419	FLEX Activity Supervisor	12	1				12	Project Supervisor
2023 W	PHAR 305	Clinical Epidemiology & Pharmaceutical	24	29	15				Course Co-coordinator

		Outcomes II							
2023 W	PHAR 548/648	Seminars in Pharmaceutical Sciences	24	71		3			Course coordinator
2022 F	PHAR 307	Directed Studies	39	1				39	Instructor
2022 F	PHAR 548/648	Seminars in Pharmaceutical Sciences	24	71		3			Course coordinator
2022 F	MEDD 419	FLEX Advisor	16.5	10		15			Instructor
2022 W	MEDD 419	FLEX Activity Supervisor	14	2				14	Project Supervisor

**(c) Students supervised:**

**(c.1) Graduate Students Supervised as Primary or Co-Supervisor**

**Description:** I supervise MSc, PhD, and postdoctoral fellows in the Faculty of Pharmaceutical Sciences, UBC. Students train in the Epidemiology and Health Outcomes Research Graduate Program on thesis projects within my research program.

Student Name	Program Type	Faculty/Department	Year		Supervisory Role	Thesis
			Start	Finish		
Kevin Yan	PhD	Medicine, Experimental Medicine	05/2024	Active	Co-Supervisor	Value of tele-PR for reducing health inequities in the burden of COPD in the US
Yiwei Yin	MSc	Pharmaceutical Sciences	2022/09	2024/12	Primary Supervisor	Measuring guideline-concordance to COPD medications
Spencer Lee	MSc	Pharmaceutical Sciences	2022/09	Active	Co-Supervisor	Air pollution and adult asthma incidence in BC
Joseph Emil Amegadzie	Postdoctoral Fellow	Pharmaceutical Sciences	2021/09	2022/09	Co-Supervisor	National trends in asthma and COPD hospitalization

**(c.2) Graduate Student (M.Sc. and Ph.D.) Supervisory Committees**

**Description:** I serve on the supervisory committee for graduate student trainees in the Faculties of Pharmaceutical Sciences and Medicine. In this role, I provide research expertise and mentorship to trainees in health economics and outcomes research.

Student Name	Program Type	Faculty/Department	Year		Supervisor	Thesis
			Start	Finish		
Mehdi Jafari	PhD	Medicine, School of Population and public health	2022/12	Active	Dr. Bradley Quon	Impact of disease modifying therapies on the burden of cystic fibrosis

Tae Yoon Lee <sup>1</sup>	PhD	Pharmaceutical Sciences	2019/09	2024/09	Dr. Mohsen Sadatsafavi	Projecting the outcomes of early interventions for asthma
Joseph Ho	MSc	Pharmaceutical Sciences	2021/09	2023/05	Dr. Mohsen Sadatsafavi	Precision Medicine and Acute Exacerbation of COPD

<sup>1</sup>**Award:** UBC 4 Year Fellowship Award

### (c.3) Visiting Graduate Student Supervision

Student Name	Program Type	Faculty/Department	Year		Supervisor y Role	Thesis
			Start	Finish		
Rachael Mountain	PhD*	Pharmaceutical Sciences	2022/09	2022/12	Primary Supervisor	Budget Impact of Case Detection for COPD in Canada

\* Visiting scholar through Mitacs Globalink

### (c.4) Research Staff Supervision

Name	Position	Year
Cristina Novakovic	Graduate Research Assistant	2024-Present
Amin Adibi, MSc	Statistical Research Analyst (0.20 FTE)	2022-Present

### (c.5) Directed Studies Student Supervision (as part of the PHRM 307)

Student Name	Degree	Year		Course (# credits)
		Start	Finish	
Michelle Kim	PharmD	2022/04	2022/06	3

### (c.6) Medical Student Supervision (as part of the FLEX Program)

**Description:** I supervise 1<sup>st</sup> year medical students on a 6-week research rotation as part of the Flexible Enhanced Learning (FLEX) program (MEDD 419).

Student Name	Degree	Year		Course (# credits)
		Start	Finish	
Dexter Kim	Doctor of Medicine (MD)	2023/04	2023/06	MEDD 419
Ravneet Sookh	Doctor of Medicine (MD)	2022/04	2022/06	MEDD 419
Sarika Verma	Doctor of Medicine (MD)	2022/04	2022/06	MEDD 419

### (c.7) UBC Science Co-op Student Supervision

**Description:** I supervise UBC Science students on 4-month work terms, which are required for students to graduate with a co-op degree designation

Student Name	Degree	Year	
		Start	Finish
Mark Ewert	BSc Mathematics	2025/01	2025/08
Ece Celik	BSc Statistics	2025/01	2025/04

### d) Continuing Education Activities

UBC, Faculty Instructional Skills Workshop, Centre for Teaching and Learning and Technology, June 6-8,

2023

UBC, Supervising Graduate Students – Key Principles and Practices Workshop, April 24, 2023

UBC, Graduate Student Supervision for New Faculty Training Webinar, March 24, 2022

## 9. SCHOLARLY AND PROFESSIONAL ACTIVITIES

### (a) Areas of special interest and accomplishments

I am a health economics and outcomes researcher specializing in simulation modeling and comparative effectiveness evaluation with applications to respiratory disease. The overarching themes of my research are **real-world evidence generation** to understand disease trajectory and patterns of care, followed by **disease simulation modeling** to evaluate healthcare interventions for reducing the burden of disease on patients and the healthcare system. My work incorporates methods from epidemiology, health economics, and data science, applied to practical questions for improving the delivery of healthcare and effectiveness of interventions in respiratory medicine.

### Disease Simulation Modeling

The focus of my activities in this area is developing a reference policy model of asthma for Canada, which we are using to evaluate a wide range of strategies for early intervention and prevention, with a focus on the impact of reducing exposure to outdoor air pollution. This involves generating evidence on the life trajectory of asthma from a variety of data sources, including administrative health databases, clinical studies, and climate modelling, and is supported by an interdisciplinary team of clinicians, environmental epidemiologists, and modelers. I am committed to involving patients and other stakeholders at all stages of model development and implementation, and work closely with patient representatives and knowledge translation specialists from the Legacy for Airway Health (<http://legacyairwayhealth.ca/>).

### (b) Research Grants

\* Indicates patient or knowledge user co-investigator

Granting Agency	Subject	CO MP	\$ Total	Year	Principal Investigator	Co-Investigators
MOH-UBCH Research Seed Grant	Access and adherence to smoking cessation programs: How are people in BC using community pharmacies?	C	\$72,250	03/2025 - 03/2026	T. Charrois	J. Yuen K. Dahri K. Duan <b>K. Johnson</b> F. Hoekstra L. Struik
Lung Health Foundation Emerging Scholar Research Award	Understanding the impacts of provincial drug policy on access to COPD inhalers from patient, provider, and healthcare payer perspectives	C	\$50,000	07/2024 - 07/2025	<b>K. Johnson</b>	M. Law K. Duan C. Carlsten A. Butcher* M. Gerald*
American Thoracic Society Research Grant	Evaluation Platform in COPD for USA (EPIC-USA)	C	\$40,000 USD	07/2024 - 07/2025	K. Duan	<b>K. Johnson</b>
CIHR Catalyst Grant: Chief Public Health Officer (CPHO) Report 2022: Mobilizing Public Health Action on Climate Change in Canada	Air Pollution and Asthma in Canada: Projections of Burden and the Value of Climate Adaptation Strategies	C	\$125,000	07/2023 - 07/2024	<b>K. Johnson</b>	C. Carlsten E. Brigham M. Brauer A. Giang A. Adibi S. Harvard

CIHR- THINC Implementation Science Team Grant	SPIRO: SPirometry for Improved Indigenous and Rural Respiratory Outcomes	C	\$1,214,124	04/2023 – 04/2027	P. Camp C. Carlsten S. Gupta L. Hedden <b>K. Johnson</b> T. Holyk SR. Olsen J. Pawlovich	B. Bingham L. Chartrand K. Duan J. Godley W. Hartford M. Li M. Nonoyama R. Rae J. Road K. Vasarhelyi C. Yang
BC Lung Association- Lung Health Research Grant	The Impact of Out-Of-Pocket Costs on Adherence to Asthma Medications	C	\$50,000	11/2022 – 11/2024	<b>K. Johnson</b>	M. Law E. Brigham M. Sadatsafavi S. Chow* R. Carter*
Canadian Institutes of Health Research – Planning and Dissemination Grant	Developing an Asthma Policy Model for Early Intervention and Prevention	C	\$14,970	06/2022 – 05/2023	<b>K. Johnson</b>	M. Sadatsafavi C. Carlsten E. Brigham S. Turvey T. To M. Brauer P. Subbarao C. Yang S. Harvard A. Adibi M. Biagtan* M. Roushorne* P. Blagden*
Canadian Institutes of Health Research – Project Grant	PLEDGE: Policies Laws and Emergency Department Guidelines for Epinephrine auto-injector use	C	\$100,000	04/2023 – 04/2024	M. Ben-Shoshan	<b>K. Johnson</b> R. Goldman J. Protudjer J. Upton
Canadian Institutes of Health Research – Project Grant	Improving Canadian Lung Cancer Screening Efficiency with a Computed Tomography Risk Classifier	C	\$914,175	04/2023 – 04/2028	B. MacDonald-Smith, M. Kirby, M. Sadatsafavi	<b>K. Johnson</b> A. Benedetti N. Ezer

**(c) Contracts**

None

**(d) Salary Support Award**

None

**(e) Invited Presentations**

**2025**

1. Pharmaceutical Policy and Access to Inhaled Medications in BC. UBC Division of Respiratory Medicine Rounds. Vancouver, BC. April 2025.  
[Regional, Audience: Researchers and clinicians]

**2023**

2. HEPA Air Filters for Preventing Wildfire-Related Asthma Complications: A Cost-effectiveness Study. BC Health and Smoke Exposure (HASE) Coordination Committee. Vancouver, BC. July 2023.  
[Provincial, Audience: Policy makers]

3. Finding Your First Academic Appointment Panel Discussion. The Canadian Lung Association RENASCENT / CIHR-ICRH Training Workshop – Montreal, QC. April 2023.  
[**National, Audience:** Trainees, Early Career Researchers]

## **2022**

4. The Impact on Out-of-Pocket Costs on Adherence to Asthma Medications. Canadian Respiratory Conference Annual General Meeting. Ottawa, ON. October 2022.  
[**National, Audience:** Researchers and clinicians]

## **2021**

5. Lifetime Medical Costs Attributable to Sickle Cell Disease among Non-Elderly Individuals with Commercial Insurance. National Heart Lung and Blood Institute Annual Sickle Cell Disease Meetings. Virtual. August 2021.  
[**National, Audience:** Patients, decision makers, researchers and clinicians]
6. Cost-Effectiveness of Case Detection Strategies for the Early Detection of COPD. Centre for Heart Lung Innovation Seminar Series. Vancouver, Canada. January 2021.  
[**Regional, Audience:** Researchers and clinicians]

## **2020**

7. Cost-Effectiveness of Case Detection Strategies for the Early Detection of COPD. Program in Health Economics and Outcomes Research Methodologies Seminar Series. Virtual. April 2020.  
[**Local, Audience:** Researchers and trainees]

## **2019**

8. Understanding disease trajectory to guide precision policy: A case study in COPD detection. Program in Health Economics and Outcomes Research Methodologies Seminar Series University of Washington, Seattle. July 2019.  
[**Local, Audience:** Researchers and trainees]

## **(f) Other Presentations**

## **2019**

1. Resource use before COPD diagnosis. Canadian Respiratory Research Network Annual General Meeting, Ottawa, Canada.

## **2018**

2. Using respiratory symptoms to distinguish between undiagnosed COPD and non-COPD. Canadian Respiratory Research Network Annual General Meeting, Ottawa, Canada. January 2018
3. The diagnostic performance of patient symptoms in screening for COPD. Faculty of Pharmaceutical Sciences Graduate Student and Postdoctoral Fellow Research Symposium, Vancouver, Canada. May 2018
4. Heterogeneity in the respiratory symptoms of patients with COPD. Collaboration for Outcomes Research and Evaluation Annual Retreat, Vancouver, Canada. May 2018
5. Characterizing undiagnosed chronic obstructive pulmonary disease: a systematic review and meta analysis. British Columbia Heart and Lung FEST, Vancouver, Canada. February 2018.

6. Stability of asthma symptom control in a longitudinal study of mild-moderate asthmatics. Canadian Respiratory Research Network Annual General Meeting, Ottawa, Canada. January 2017.

**(g) Media and news outlet mentions resulting arising from PUBLISHED research\_**

**Arising from first authored publication: Johnson KM**, Cheng L, Yin Y, Carter R, Chow S, Brigham E, Law MR. The Impact of Eliminating Out-of-Pocket Payments on Asthma Medication Use. *Ann Am Thorac Soc*. 2024 Aug 6. PMID: 39106523.

2025 (Feb 7) *Vancouver Coastal Health Research Insider*. Calculating how the cost of medication affects asthma patient care. <https://www.vchri.ca/stories/2025/02/07/calculating-how-cost-medication-affects-asthma-patient-care>

**Arising from first authored publication: Johnson KM**, Jiao B, Ramsey S, Bender MA, Devine B, Basu A. Lifetime Medical Costs Attributable Sickle Cell Disease among Non-Elderly Individuals with Commercial Insurance. *Blood Advances*. <https://doi.org/10.1182/bloodadvances.2021006281> [PA, IF: 6.799]

2023 (Dec 8) *The New York Times*. F.D.A. Approves Sickle Cell Treatments, Including One That Uses CRISPR. <https://www.nytimes.com/2023/12/08/health/fda-sickle-cell-crispr.html>

2022 (May 19) *HealthDay* Burden of Medical Costs for Sickle Cell Disease Quantified <https://consumer.healthday.com/burden-of-medical-costs-for-sickle-cell-disease-quantified-2657334367.html>

2022 (May 19) *Sickle Cell Anemia News* SCD Patients' Lifetime Medical Costs Come to \$1.7M, Partly Out of Pocket <https://sicklecellanemianews.com/2022/05/19/scd-patients-lifetime-medical-costs-come-1-7-million-partly-out-pocket/>

**Arising from senior authored publication: Amegadzie JE**, Lee TY, Sadatsafavi M, Lynd LL, Sin D, **Johnson KM**. 16-year trends in COPD hospital admissions in Canada. *CMAJ*. 2023 Sept 11;195(35): E1172-E1179.

2023 (Sept 11) *Hospital admissions for COPD increased substantially, especially in women and younger people* <https://e1.engage.com/ct/3660/3171746/785484820/7d4acf98aacb1709d1a70dce9a035825>

2023 (Sept 25) *COPD hospitalizations have risen by nearly 70% since 2002 in Canada* <https://www.healio.com/news/pulmonology/20230925/copd-hospitalizations-have-risen-by-nearly-70-since-2002-in-canada>

**Arising from first authored publication: Johnson KM**, Cheng L, Yin Y, Carter R, Chow S, Brigham E, Law M. Impact of income-based public drug coverage deductibles on adherence to asthma medications. *Annals of Allergy, Asthma & Immunology*. 2023. doi:10.1016/j.anai.2023.10.017.

2023 (Nov 7) Deductibles do not impact asthma medication use, adherence in British Columbia <https://www.healio.com/news/allergy-asthma/20231107/deductibles-do-not-impact-asthma-medication-use-adherence-in-british-columbia>

## 10. SERVICE TO THE UNIVERSITY

### (a) Memberships on committees, including offices held and dates

#### Faculty Level Committees

Faculty	Committee	Dates
<i>Standing Committees</i>		
Centre for Lung Health	Patient-Oriented Research Training Sub-Committee	2025
Centre for Lung Health	Strategic Planning Committee (trainee pillar co-lead)	2025
Pharmaceutical Sciences	Bachelor of Pharmaceutical Sciences Curriculum Working Group	2025-2026
Pharmaceutical Sciences	Faculty of Pharmaceutical Sciences Graduate Admissions Committee	2022 - 2023
<i>Undergraduate Student Admissions</i>		
Pharmaceutical Sciences	Bachelor's of Pharmaceutical Sciences (BPSc) Screening Committee	2025-2026 2022 - 2023
<i>Thesis Examination Committee Chair</i>		
School of Population and Public Health, Faculty of Medicine	MSc Defense for Shania Au: The impact of reference pricing on prescribing patterns, costs and health services utilization of proton pump inhibitors and statins in British Columbia	June 21, 2022

### (b) Other service, including dates

Role/Committee	Dates
1. Department of Medicine Research Expo	
Judge	June 2025
2. FoPS Graduate Student and Postdoctoral Research Symposium	
Judge	May 2022

## 11. SERVICE TO THE COMMUNITY

### (a) Memberships on scholarly societies, including offices held and dates

<b>Member</b> , Canadian Respiratory Research Network	2016 – Ongoing
<b>Member</b> , International Society for Health Economics and Outcomes Research	2020 – Ongoing

### (b) Memberships on other societies, including offices held and dates

1. **Co-lead**, Health Economics Methodology Meeting (HEMM) 2022 – Ongoing

**Description:** The Health Economics Methodology Meeting (HEMM) group consists of academics in British Columbia with an interest in health economics methodology. Our organizational activities are centered around an annual meeting, which I have co-led with two colleagues since July 2022. The purpose of the meeting is to critically discuss papers in the area of health economics, providing scholars and students an opportunity for constructive dialogue with national and international leaders in health economics. The event brings together researchers from BC Cancer, the Centre for Clinical Epidemiology and Evaluation (C2E2; Vancouver Coastal Health Research Institute), the Centre for Advancing Health Outcomes (St. Paul's Hospital), the Centre for Health Services Research and Policy (CHSPR; University of British Columbia (UBC)), the Collaboration for Outcomes Research and Evaluation (CORE; UBC), University of Washington, and University of Calgary. Annual meetings are comprised of discussion of work-in-progress research papers and a plenary session delivered by an internationally renowned health economist.

2. **Lead**, FLIGHT Practicum Coordinator 2022 – Ongoing

**Description:** The future leaders in epidemiology and health outcomes research (FLIGHT) training program is comprised of MSc and PhD students in the Collaboration for Outcomes Research and

Evaluation (CORE) within the Faculty of Pharmaceutical Sciences, UBC. Its objectives are to provide students with the academic courses, professional development, practicum opportunities, and funding necessary to launch successful careers in health economics and outcomes research. As leader of the practicum component of FLIGHT, I collaborated with Canada's Drug Agency (CDA), the largest health-technology assessment organization in Canada, to create a summer internship program for our FLIGHT students. Students are offered 12-week paid internships in a variety of CDA departments suited to their skill set, such as evidence appraisal, real-world evidence, and health policy decision-making. Our program launched in May 2023, with 2 FLIGHT students beginning their internships. No students elected to do an internship in 2024, however the program is ongoing and we expect to have several students begin internships in 2025.

**(c) Reviewer (journal, agency, etc. including dates)**

**Journal Reviews**

Respiratory Medicine	June 2025
European Respiratory Journal	May 2025
Annals of Internal Medicine (Elevate)	February 2025
ERJ Open	February 2025
Pharmacoeconomics	December 2024
CHEST	October 2024
CHEST	May 2023
Canadian Journal of Respiratory Critical Care and Sleep Medicine	May 2023
Thorax	December 2022
Canadian Journal of Respiratory Critical Care and Sleep Medicine	November 2022
Journal of Allergy and Clinical Immunology: In Practice	July 2022
Canadian Medical Association Journal	May 2022
Nature Human Behaviour	January 2022
BMC Pulmonary Medicine	December 2021
Lancet Respiratory Medicine	November 2021
Lancet Regional Health	November 2021
Canadian Medical Association Journal	July 2021
Canadian Journal of Respiratory Critical Care and Sleep Medicine	July 2021
International Journal of Chronic Obstructive Pulmonary Disease	July 2021
International Journal of Chronic Obstructive Pulmonary Disease	December 2020
International Journal of Chronic Obstructive Pulmonary Disease	December 2020
Journal of Allergy and Clinical Immunology: In Practice	May 2020
Respiratory Research	April 2019
Scientific Reports	July 2019
European Journal of Health Economics	July 2019

**Conference Abstract Reviews**

The Professional Society for Health Economics and Outcomes Research (ISPOR) (for May 2020)	January 2020
--	--------------

## Grant Reviews

Standing committees	Dates
<b>1. Lung Health Foundation Research Review Committee</b>  <b>Description:</b> The Lung Health Foundation is a national non-profit organization in Canada. I was invited to be a member of the Patient, Health Systems and Population Research review committee, which reviews applications for 2-3 funding opportunities per year.	2025 - ongoing
<b>Grant Reviews for National Agencies</b>	
<b>2. Lung Health Foundation Mid-Career Research Award</b>	October 2024

### (g) External examiner (indicate universities and dates)

Student Name	Degree	Program	Date
Minh-Tri Van	MSc	Faculty of Pharmaceutical Sciences, UBC	August 2023
Michael Asamoah-Boaheng	PhD	Memorial University, Faculty of Medicine	July 2022

### (d) Consultant

Organization	Dates
<b>1. QuitNow Evaluation – Consultation for the BC Ministry of Health</b>  <b>Description:</b> I served as a health economic consultant for an independent review of QuitNow smoking cessation services in BC. I led the return on investment portion of the evaluation, and our findings were presented to members of the Population and Public Health Division at the BC Ministry of Health.	2025

## 12. AWARDS AND DISTINCTIONS

### (a) Awards for Teaching (indicate name of award, awarding organizations, date)

None

### (b) Awards for Scholarship (indicate name of award, awarding organizations, date)

Scientist Awards	Dates
Michael Smith Health Research BC Scholar Award (\$450,000)	2024 – 2029
BC Lung Foundation Award of Excellence in Lung Health Research	2023

Trainee Awards	Dates
<b>PhD</b>	
Mitchell-Dwivedi Graduate Award in Pharmaceutical Sciences, University of British Columbia (\$12,650)	2020
Institute of Health Services and Policy Research Travel Award, Canadian Institutes of Health Research (\$1,500)	2019
Symposium Travel Award, Canadian Agency for Drugs and Technologies in Health (\$1,650)	2019
John H. McNeill Award, University of British Columbia (\$2,300)	2019
Santosh M. Wasam Travel Award, University of British Columbia (\$1,000)	2019
Institute of Circulatory and Respiratory Health Travel Award, Canadian Institutes of Health Research (\$2000)	2018, 2017
Four Year Doctoral Fellowship, University of British Columbia (\$72,800)	2017

Studentship Award, The Canadian Lung Association (\$42,000)	2017
<b>MSc</b>	
Douglas and Jean Bailey Award, University of British Columbia (\$1,700)	2016
Graduate Student Award, Faculty of Pharmaceutical Sciences (\$2,000)	2016
Bert Hoffmeister Award, University of British Columbia (\$3,500)	2014
Canadian Graduate Scholarship, Natural Sciences and Engineering Research Council of Canada (\$17,500)	2014
Hesse Graduate Award, University of British Columbia (\$1,800)	2014
BRITE Research Award, University of British Columbia (\$10,000)	2013
<b>BSc</b>	
Undergraduate Research Award, Natural Sciences and Engineering Research Council of Canada (\$4,500)	2012

**(c) Awards for Service (indicate name of award, awarding organizations, date)**

<b>Trainee Awards</b>	<b>Dates</b>
Outstanding Service Award, Faculty of Pharmaceutical Sciences	2019, 2018

**(d) Other Awards**

<b>Award and Organization/Institution</b>	<b>Dates</b>
Network of Alberta Health Economists Thesis Throwdown Competition (1 <sup>st</sup> place)	2019
Canadian Respiratory Research Network Annual General Meeting (Best Trainee Presentation)	2019

**University of British Columbia  
Publications Record**

**Date:** April 7, 2025

**Initial:** KJ

**SURNAME:** Johnson

**FIRST NAME:** Kate

**MIDDLE NAME(S):** Marie

**1. REFEREED PUBLICATIONS**

**(a) Journals**

**Summary**

Total (as of CV date): **41**; **25** as PA/SA

**Key to Contributions**

**PA:** primary author, **SA:** senior author, **MC:** major contributor (59-89%), **CA:** contributing author (10-49%), **IF:** journal impact factor (at time of publication)

Underlined co-author names are trainees

**2025**

1. Yin Y, Mehareen J, Sadatsafavi M, Brigham E, De Vera MA, Duan KI, **Johnson KM**. Factors associated with guideline-concordant maintenance inhaled medication for COPD: a population-based, longitudinal cohort study. Thorax. 2025 Aug 18: thorax-2025-223544. PMID: 40829877. [**SA**, **IF: 10.8**]
2. Mehareen J, Yin Y, Choy K, **Johnson KM**, Sin DD, Sadatsafavi M. Trends and Regional Differences in the Use of Maintenance Inhaled Medications in COPD: A Population-Based Study. J Gen Intern Med. 2025 Jul 16. PMID: 40775112. [**CA**, **IF: 6.5**]
3. Yin Y, Mok V, Jeong J, Brigham E, De Vera MA, Sadatsafavi M, Duan KI, **Johnson KM**. Guideline-Concordant Inhaled Medication Use in COPD: A Systematic Review of Definitions Used in Administrative Health Data. ERJ Open. 2025 00123-2025. [**SA**, **IF: 4.3**]
4. Yin Y, Shoshan MB, Shaker M, Greenhawt M, **Johnson KM**. Cost-Effectiveness of Watchful Waiting versus Immediate Emergency Department Transfer after Epinephrine Autoinjector Use in Canada. Allergy Asthma Clin Immunol. 2025 Jan 22;21(1):5. PMID: 39844311. [**SA**, **IF: 3.5**]

**2024**

5. Lee S, Tian D, He R, Cragg JJ, Carlsten C, Giang A, Gill PK, **Johnson KM\***, Brigham E\*. Ambient air pollution exposure and adult asthma incidence: a systematic review and meta-analysis. Lancet Planet Health. 2024 Dec;8(12):e1065-e1078. PMID: 39674196. \*co-senior authors [**co-SA**, **IF: 24.1**]
6. Lee TY, Petkau J, Saatchi A, Marra F, Turvey SE, Lishman H, Patrick DM, Cragg JJ, **Johnson KM**, Sadatsafavi M. Impact analysis of infant antibiotic exposure on the burden of asthma: a simulation modeling study. Front Allergy. 2024 Dec 23;5:1491985. PMID: 39764437. [**CA**, **IF: 3.3**]
7. **Johnson KM**, Cheng L, Yin Y, Carter R, Chow S, Brigham E, Law MR. The Impact of Eliminating Out-of-Pocket Payments on Asthma Medication Use. Ann Am Thorac Soc. 2024 Aug 6. PMID: 39106523. [**FA**, **IF: 6.8**]

8. Mountain R, Duan K, **Johnson KM**. Benefit-harm analysis of earlier initiation of triple therapy for prevention of acute exacerbations in patients with COPD. *Ann Am Thorac Soc*. 2024 Aug;21(8):1139-1146. PMID: 38578813 [[SA](#), IF: 6.8]
9. **Johnson KM**, Duan K. The growing burden of COPD in the US (Editorial). *CHEST*. 2024 May;165(5):1027-1028. PMID: 38252942 [[FA](#), IF: 9.5]
10. Basu A, Winn AN, **Johnson KM**, Jiao B, Devine B, Hankins JS, Arnold SD, Bender MA, Ramsey SD. Gene therapy versus common care for eligible individuals with sickle cell disease in the US: a cost-effectiveness analysis. *Ann Intern Med*. 2024 Feb;177(2):155-164. PMID: 38252942 [[CA](#), IF: 39.2]
11. Adibi A, Barn P, Shellington E, Harvard S, **Johnson KM\***, Carlsten C\*. HEPA Air Filters for Preventing Wildfire-Related Asthma Complications, a Cost-effectiveness Study. *American Journal of Respiratory and Critical Care Medicine*. 2024 Jan 15;209(2):175-184. PMID: 37917367 \*co-senior authors [[co-SA](#), IF: 24.7]

## **2023**

12. Ho J, Shaker M, Greenhawt M, Sadatsafavi M, Abrams EM, Oppenheimer J, Mosnaim GS, Lee TY, **Johnson KM**. Cost-effectiveness of over-the-counter as-needed budesonide-formoterol versus inhaled epinephrine in US adults with mild asthma. *Ann Allergy Asthma Immunol*. 2023:S1081-1206(23)01352-2. PMID: 37879568 [[SA](#), IF: 5.9]
13. **Johnson KM**, Cheng L, Yin Y, Carter R, Chow S, Brigham E, Law M. Impact of income-based public drug coverage deductibles on adherence to asthma medications. *Ann Allergy Asthma Immunol*. 2023:S1081-1206(23)01345-5. PMID: 37871771 [[FA](#), IF: 5.9]
14. Ahmadian S, **Johnson KM**, Ho JK, Sin DD, Lynd LD, Harrison M, Sadatsafavi M. A Cost-Effectiveness Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc*. 2023 Sep 13. PMID: 37703432 [[CA](#), IF: 8.3]
15. Amegadzie JE, Lee TY, Sadatsafavi M, Lynd LL, Sin D, **Johnson KM**. Trends in hospital admissions for chronic obstructive pulmonary disease over 16 years in Canada. *CMAJ*. 2023 Sept 11;195(35): E1172-E1179. PMID: 37696554 [[SA](#), IF: 17.4]
16. Mountain R, Kim D, **Johnson KM**. Budget impact analysis of adopting primary care-based COPD case detection in the Canadian general population. *CMAJ Open*. 2023 Nov 7;11(6):E1048-E1058. PMID: 37935489 [[SA](#), IF: 3.1]
17. Jiao B, **Johnson KM**, Ramsey SD, Bender MA, Devine B, Basu A. Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries. *Blood Advances*. 2023 Jul 11;7(13):3276-3283. PMID: 36929166 [[CA](#), IF: 7.5]

## **2022**

18. Ho JK, Safari A, Adibi A, Sin DD, **Johnson KM**, Sadatsafavi M; IMPACT study. Generalizability of Risk Stratification Algorithms for Exacerbations in COPD. *CHEST*. 2022 Dec 9:S0012-3692(22)04216-7. PMID: 36509123 [[CA](#), IF: 10.26]
19. Ramsey SD, Bender MA, Li L, **Johnson KM**, Jiao B, Devine B, Basu A. Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance-A retrospective cohort study. *PLoS One*. 2022 Nov 29;17(11):e0278137. PMID: 36445914 [[CA](#), IF: 3.752]
20. **Johnson KM**, Jiao B, Bender MA, Ramsey S, Devine B, Basu A. Development of a Conceptual Model for Evaluating New Non-Curative and Curative Therapies for Sickle Cell Disease. *PLOS ONE*. 2022 17(4): e0267448. PMID: 35482721 [[PA](#), IF: 3.752]

21. **Johnson KM**, Jiao B, Ramsey S, Bender MA, Devine B, Basu A. Lifetime Medical Costs Attributable Sickle Cell Disease among Non-Elderly Individuals with Commercial Insurance. *Blood Advances*. 2023 Feb 14;7(3):365-374. PMID: 35575558 [**PA**, **IF: 7.5**]
22. Baldwin, Z, Jiao B., Basu A, Roth J, Bender MA, Elsisi Z, **Johnson KM**, Cousin E, Ramsey SD, Devine B. Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis. *PharmacoEconomics Open*. 2022 Jul;6(4):469-481. PMID: 35471578 [**CA**, **IF: 1.69**]
23. **Johnson KM**. A longitudinal approach to assessing patterns of healthcare utilization. *CAN J RESP CRIT CARE*. 2022; 6(2): 76–77. [**PA**, **IF: 0.80**]

## **2021**

24. **Johnson KM**, Sadatsafavi M, Adibi A, Lynd LD, Harrison M, Tavakoli H, Sin DD, Bryan S. Cost-Effectiveness of Case Detection Strategies for the Early Detection of COPD. *Appl Health Econ Health Policy*. 2021;19: 203-215. PMID: 33135094 [**PA**, **IF: 2.561**]

## **2020**

25. Adibi A, Sin DD, Safari A, **Johnson KM**, Aaron SD, FitzGerald JM, Sadatsafavi M. The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study. *Lancet Respiratory Medicine*. 2020; 8(10):1013-1021. PMID: 32178776 [**CA**, **IF: 30.700**]
26. **Johnson KM**, Khakban A, Bryan S, Sin DD, Sadatsafavi M. Healthcare system encounters before COPD diagnosis: a registry-based longitudinal cohort study. *Thorax*. 2020;75(2):108-115. PMID: 31704794 [**PA**, **IF: 10.31**]
27. Ng BC, Leslie WD, **Johnson KM**, FitzGerald JM, Sadatsafavi M, Chen W. Effects of long-term inhaled corticosteroid treatment on fragility fractures in older women: the Manitoba BMD registry study. *Osteoporosis International*. 2020;31(6):1155-1162. PMID: 32123939 [**CA**, **IF: 3.591**]
28. Yaghoubi M, Adibi A, Zafari Z, FitzGerald JM, Aaron SD, **Johnson KM**, Sadatsafavi M. Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States. *J Allergy Clin Immunol*. 2020 May;145(5):1367-1377. PMID: 31837372 [**CA**, **IF: 10.79**]

## **2019**

29. Al Efraij K, **Johnson KM**, Wiebe D, Sadatsafavi M, FitzGerald JM. A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma. *J Asthma*. 2019;56(12):1334-1346. PMID: 30513226 [**MC**, **IF: 2.515**]
30. Ng BC, Sadatsafavi M, Safari A, FitzGerald JM, **Johnson KM**. Direct costs of overdiagnosed asthma: a longitudinal, population-based cohort study in British Columbia, Canada. *BMJ Open*. 2019;9(11):e031306. PMID: 31699732 [**SA**, **IF: 2.692**]
31. Tavakoli H, **Johnson KM**, FitzGerald JM, Sin DD, Gershon AS, Kendzerska T, Sadatsafavi M. Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada. *Int J Chron Obstruct Pulmon Dis*. 2019;14:2003-2013. PMID: 31564848 [**CA**, **IF: 3.157**]
32. Sadatsafavi M, Ghanbarian S, Adibi A, **Johnson KM**, FitzGerald JM, Flanagan W, Bryan S, Sin D. Development and Validation of the Evaluation Platform in COPD (EPIC): A Population-Based Outcomes Model of COPD for Canada. *Medical Decision Making*. 2019 Feb;39(2):152-167. PMID: 30678520 [**CA**, **IF: 2.583**]

## **2018**

33. **Johnson KM**, Safari A, Tan WC, Bourbeau J, FitzGerald JM, Sadatsafavi M. Heterogeneity in the respiratory symptoms of patients with mild-to-moderate COPD. *Int J Chron Obstruct Pulmon Dis*. 2018;13:3983-3995 [**PA**, **IF: 3.157**]
34. **Johnson KM**<sup>†</sup>, Chen W<sup>†</sup>, FitzGerald JM, Sadatsafavi M, Leslie WD. Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study. *Archives of Osteoporosis*. 2018 Oct 29;13(1):116. PMID: 30374631 <sup>†</sup>co-first authors [**PA**, **IF: 2.583**]
35. **Johnson KM**, Tan WC, Bourbeau J, Sin DD, Sadatsafavi M. The diagnostic performance of patient symptoms in screening for COPD. *Respiratory Research*. 2018 Aug 3;19(1):147. PMID: 30075717 [**PA**, **IF: 5.631**]
36. **Johnson KM**, Bryan S, Ghanbarian S, Sin DD, Sadatsafavi M. Characterizing undiagnosed chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Respiratory Research*. 2018 Feb 7;19(1):26. PMID: 29415723 [**PA**, **IF: 5.631**]
37. Sadatsafavi M, Xie H, Etminan M, **Johnson KM**, FitzGerald JM. The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology. *PLoS One*. 2018;13(1):e0191243. PMID: 29351331 [**CA**, **IF: 3.24**]

## **– 2017**

38. **Johnson KM**, FitzGerald JM, Tavakoli H, Chen W, Sadatsafavi M. Stability of Asthma Symptom Control in a Longitudinal Study of Mild-Moderate Asthmatics. *J Allergy Clin Immunol Pract*. 2017;5(6):1663-1670. PMID: 28499773 [**PA**, **IF: 8.861**]
39. **Johnson KM**, Germain RR, Tarwater CE, Reid JM, Arcese P. Demographic consequences of invasion by a native, controphic competitor to an insular bird population. *Oecologia*. 2018 May;187(1):155-165. PMID: 29500488 [**PA**, **IF: 3.011**]
40. Morrell N, **Johnson KM**, Tarwater CE, Arcese P. Nest defense and parental investment in Song Sparrows (*Melospiza melodia*). *CAN J ZOOL*. 2016. 94 (7), 473-477 [**MC**, **IF: 1.597**]
41. **Johnson KM**, Nielsen SE. Demographic effects on fruit set in the dioecious shrub Canada buffaloberry (*Shepherdia canadensis*). *PeerJ*. 2014;2:e526. [**PA**, **IF: 2.984**]

## **(b) Conference Proceedings**

### **Summary**

Total (as of CV date): 13; 11 as PA/SA

### **Key to Contributions**

**PA**: primary author, **SA**: senior author, **MC**: major contributor (59-89%), **CA**: contributing author (10-49%), **IF**: journal impact factor (at time of publication)

Underlined co-author names are trainees

## **2025**

1. Yin Y, Mehareen J, Sadatsafavi M, Brigham E, De Vera M, Duan KI, and **Johnson KM**. Factors Associated with Guideline-Concordant Maintenance Inhaled Medication for COPD: A Population-Based, Longitudinal Cohort Study. *Am J Respir Crit Care Med* 2025;211:A4949. [**SA**]

2. **Johnson KM**, Carlsten C, Harvard S, Winsberg EB, and Adibi A. The Impact of Time Scale on the Cost-Effectiveness of Air Cleaners for Reducing Exposure to Air Pollution From Wildfires [abstract]. Am J Respir Crit Care Med 2025;211:A5413. **[FA]**
3. Yan K, Duan K, and **Johnson KM**. Development and Validation of EPIC-USA: A COPD Policy Model for the United States. Am J Respir Crit Care Med 2025;211:A7130. **[SA]**
4. Lee S, Adibi A, Giang A, Carlsten C, Paul N, Brigham E, and **Johnson KM**. Evaluating the Long-Term Cost-Effectiveness of a Government Rebate Program for Air Cleaners in Preventing Asthma in British Columbia, Canada. Am J Respir Crit Care Med 2025;211:A7402. **[SA]**
5. Adibi A, Brigham EP, Cleland S, **Johnson KM**, Camp PG, and Carlsten C. Mapping Disparities in Access to Spirometry. Am J Respir Crit Care Med 2025;211:A7213. **[MC]**

## **2024**

6. Yin, Y., Mok V, Jeong J, Brigham E, De Vera M, Sadatsafavi M, **Johnson KM**. Defining guideline-concordant inhaled medication use in COPD: A systematic review of definitions used in administrative health data. Can J Respir Crit Care Sleep Med. 2024;8(sup1):S39. **[SA]**
7. Lee S, Tian D, Cragg JJ, Carlsten C, Giang A, Gill P, **Johnson KM\***, Brigham E\*. Outdoor air pollution exposure and adult asthma incidence: a systematic review and meta-analysis. Can J Respir Crit Care Sleep Med. 2024;8(sup1):S39. p. 27-28. \*co-senior authors **[co-SA]**

## **2023**

8. Yin, Yiwei, Moshe Shoshan, Marcus Shaker, Matthew Greenhawt, and **Kate M Johnson**. Cost-Effectiveness of Watchful Waiting vs Immediate Emergency Department Transfer After Epinephrine Autoinjector Use in Canada. J Allergy Clin Immunol 153, no. 2 (February 1, 2024): AB204. **[SA]**
9. Mountain R, **Johnson KM**. Budget impact analysis of adopting primary care-based COPD case detection in the Canadian general population. ISPOR Annual Meeting. Boston, MA. May 7-10, 2023. **[SA]** *\*Ranked in the top 5% of student submitted abstracts*
10. Adibi A, **Johnson KM**, Barn P, Shellington E, Harvard S, Carlsten C. Cost-effectiveness of a Portable HEPA Air Cleaner Distribution Program to Reduce Asthma Complications in British Columbia. American Thoracic Society Annual Meeting. Washington, DC. May 19-24, 2023. **[MC]**
11. Ho J, Shaker M, Greenhawt M, Sadatsafavi M, Abrams EM, Oppenheimer J, Mosnaim GS, Lee TY, **Johnson KM**. Cost-effectiveness of over-the-counter as-needed budesonide-formoterol versus inhaled epinephrine in US adults with mild asthma. American Academy of Allergy, Asthma, and Immunology Annual Meeting, San Antonio, TX. February 24-27, 2023. **[SA]**

## **2021**

12. Baldwin Z, Jiao B, **Johnson KM**, Basu A, Roth J, Bender MA, Ramsey S, Devine, B. Economic Impact of Sickle Cell Disease, Treatments and Related Complication. International Society for Pharmacoeconomics and Outcomes Research Conference (virtual). May 17-20, 2021. **[CA]**

## **2019**

13. Ng BC, Sadatsafavi M, Safari A, FitzGerald JM, **Johnson KM**. The Costs of Misdiagnosed Asthma in a Longitudinal Study of the General Population. Canadian Respiratory Conference. Ottawa, Canada. April 11-13, 2019. **[SA]**

## **2018**

14. **Johnson KM**, Khakban A, Bryan S, Sin DD, Sadatsafavi M. Healthcare Services Use Before COPD Diagnosis: A Registry-based Longitudinal Cohort Study. Canadian Respiratory Conference.

Ottawa, Canada. April 11-13, 2019. [PA]

15. **Johnson KM**, Safari A, Tan W, Bourbeau J, Sadatsafavi M. Drivers of respiratory symptoms in COPD patients. European Respiratory Congress. Paris, France. September 15-19, 2018. [PA]
16. **Johnson KM**, Tan W, Bourbeau J, Sadatsafavi M. The discriminatory capacity of symptoms to distinguish undiagnosed COPD from non-COPD. Paris, France. European Respiratory Congress. September 15-19, 2018. [PA]
17. **Johnson KM**, Bryan S, Ghanbarian S, Sin DD, Sadatsafavi M. Characterizing undiagnosed chronic obstructive pulmonary disease: a systematic review and meta-analysis. Canadian Respiratory Conference. Vancouver, Canada. April 12-14, 2018. [PA]

## **2017**

18. **Johnson KM**, FitzGerald JM, Tavakoli H, Chen W, Sadatsafavi M. Stability of asthma symptom control in a longitudinal study of mild–moderate asthmatics. Canadian Respiratory Conference. Montreal, Canada. April 27-29, 2017. [PA]

## **2. NON-REFEREED PUBLICATIONS**

### **(a) Journals**

None

### **(b) Conference Proceedings**

None

### **(c) Other**

## **3. BOOKS**

### **(a) Authored**

None

### **(b) Edited**

None

### **(c) Chapters**

None

## **4. PATENTS**

None

## **5. SPECIAL COPYRIGHTS**

None

## **6. ARTISTIC WORKS, PERFORMANCES, DESIGNS**

None

7. **OTHER WORKS**

None

8. **WORK SUBMITTED** (including publisher and date of submission)